Biocartis

Biocartis is an innovative commercial stage molecular diagnostics (MDx) company providing next generation diagnostic solutions aimed at improving clinical practice for the benefit of patients, clinicians, payers and industry. The Company’s proprietary MDx Idylla™ platform is a fully automated, real time system which offers accurate, highly-reliable molecular information from any biological sample in virtually any setting. Idylla™ addresses the growing demand for personalized medicine by allowing fast and effective treatment selection and treatment progress monitoring. Biocartis is developing and marketing a rapidly expanding test menu addressing key unmet clinical needs in oncology and infectious diseases. These areas represent respectively the fastest and largest growing segments of the US$5 billion MDx market1 which is expected to grow to approximately US$8 billion in 2018.
Type
Public
HQ
Mechelen, BE
Founded
2007
Employees
278 (est)
Biocartis was founded in 2007 and is headquartered in Mechelen, BE

Key People at Biocartis

Ann De Meulenaere

Ann De Meulenaere

Head of the Legal Department
Ulrik Cordes

Ulrik Cordes

Chief Commercial Officer
Amit Bose

Amit Bose

Director Systems Engineering
Jose Gil

Jose Gil

Chief Information Officer
Chris Gabriels

Chris Gabriels

Director of Operations
Nader Donzel

Nader Donzel

Co-Founder and CTO

Biocartis Locations

Mechelen, BE

Biocartis Metrics

Biocartis Summary

Market capitalization

€384 B

Closing share price

€8.31
Biocartis's latest market capitalization is €384 B.

Biocartis Market Value History

Biocartis Company Life